Industry analysis shows commercial headwinds for gene therapy: runaway costs, limited patient uptake and regulatory challenges have damped the field’s commercial momentum. Companies report pricing and access hurdles; some developers have paused or reprioritized programs amid tougher reimbursement and manufacturing realities. The pullback is prompting a shift toward more pragmatic development strategies — smaller, targeted indications, payer‑friendly economics and platform optimization. Investors and developers will watch regulatory guidance, real‑world utilization and new reimbursement models that could either revive or further constrain the field.